Should I buy or sell 4D Molecular Therapeutics stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 4D Molecular Therapeutics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" FDMT shares. View FDMT analyst ratings or view top-rated stocks .

What is 4D Molecular Therapeutics' stock price target for 2024?

10 Wall Street research analysts have issued 1 year price targets for 4D Molecular Therapeutics' stock. Their FDMT share price targets range from $24.00 to $81.00. On average, they predict the company's share price to reach $44.22 in the next year. This suggests a possible upside of 75.1% from the stock's current price. View analysts price targets for FDMT or view top-rated stocks among Wall Street analysts .

How have FDMT shares performed in 2024?

4D Molecular Therapeutics' stock was trading at $20.26 at the start of the year. Since then, FDMT stock has increased by 24.6% and is now trading at $25.25. View the best growth stocks for 2024 here .

Are investors shorting 4D Molecular Therapeutics?

4D Molecular Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 9,320,000 shares, an increase of 9.6% from the March 15th total of 8,500,000 shares. Based on an average daily volume of 1,170,000 shares, the short-interest ratio is presently 8.0 days. View 4D Molecular Therapeutics' Short Interest .

When is 4D Molecular Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our FDMT earnings forecast .

How were 4D Molecular Therapeutics' earnings last quarter?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) announced its quarterly earnings results on Thursday, February, 29th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by $0.09. The business had revenue of ($0.02) million for the quarter, compared to the consensus estimate of $4.67 million. 4D Molecular Therapeutics had a negative net margin of 436.30% and a negative trailing twelve-month return on equity of 34.14%.

What ETFs hold 4D Molecular Therapeutics' stock?

ETFs with the largest weight of 4D Molecular Therapeutics (NASDAQ:FDMT) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON) , Virtus LifeSci Biotech Clinical Trials ETF (BBC) and ALPS Medical Breakthroughs ETF (SBIO) . iShares Micro-Cap ETF (IWC) .

When did 4D Molecular Therapeutics IPO?

4D Molecular Therapeutics (FDMT) raised $101 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, Evercore ISI and William Blair acted as the underwriters for the IPO and Chardan was co-manager.

Who are 4D Molecular Therapeutics' major shareholders?

4D Molecular Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include David Kirn, David Schaffer , Global Investors Lp Viking, Jacob Chacko, Robert Young Kim and Scott Bizily. View institutional ownership trends .

How do I buy shares of 4D Molecular Therapeutics?

Shares of FDMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:FDMT

4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free FDMT Stock Alerts

$25.25

+0.47 (+1.90%)

(As of 04/19/2024 ET)

Compare

Today's Range: $24.38
▼
$25.56
50-Day Range: $24.78
▼
$35.87
52-Week Range: $9.44
▼
$36.25

Volume: 634,769 shs
Average Volume: 643,216 shs
Market Capitalization: $1.29 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $44.22

Get 4D Molecular Therapeutics alerts:

4D Molecular Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 75.1% Upside
$44.22 Price Target
Short Interest: Bearish
18.22% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.88
Based on 20 Articles This Week
Insider Trading: Selling Shares
$4.18 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.03) to ($3.15) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.86 out of 5 stars

Medical Sector

398th out of 911 stocks

Biological Products, Except Diagnostic Industry

55th out of 147 stocks

4.5

Analyst's Opinion

Consensus Rating
4D Molecular Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
4D Molecular Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
18.22% of the outstanding shares of 4D Molecular Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
4D Molecular Therapeutics has a short interest ratio ("days to cover") of 8.
Change versus previous month
Short interest in 4D Molecular Therapeutics has recently increased by 9.65%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
4D Molecular Therapeutics does not currently pay a dividend.
Dividend Growth
4D Molecular Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for FDMT.

2.7

News and Social Media Coverage

News Sentiment
4D Molecular Therapeutics has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 20 news articles for 4D Molecular Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 9 people have searched for FDMT on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added 4D Molecular Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, 4D Molecular Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,179,299.00 in company stock.
Percentage Held by Insiders
10.70% of the stock of 4D Molecular Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
99.27% of the stock of 4D Molecular Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for 4D Molecular Therapeutics are expected to decrease in the coming year, from ($3.03) to ($3.15) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of 4D Molecular Therapeutics is -9.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of 4D Molecular Therapeutics is -9.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
4D Molecular Therapeutics has a P/B Ratio of 3.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About 4D Molecular Therapeutics Stock (NASDAQ:FDMT)

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

FDMT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

FDMT Stock News Headlines

April 20, 2024 | insidertrades.com

Scott Bizily Sells 1,750 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock

April 19, 2024 | insidertrades.com

Insider Selling: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Sells 1,750 Shares of Stock

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

April 4, 2024 | insidertrades.com

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Sells $259,102.34 in Stock

March 31, 2024 | insidertrades.com

Scott Bizily Sells 5,833 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock

April 17, 2024 | msn.com

4D Molecular Therapeutics (FDMT) Price Target Increased by 5.81% to 53.24

April 17, 2024 | americanbankingnews.com

4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up After Analyst Upgrade

April 17, 2024 | americanbankingnews.com

4D Molecular Therapeutics (NASDAQ:FDMT) Trading 2.5% Higher After Analyst Upgrade

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 16, 2024 | americanbankingnews.com

4D Molecular Therapeutics (NASDAQ:FDMT) Receives New Coverage from Analysts at Barclays

April 16, 2024 | americanbankingnews.com

4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Increased to $40.00 by Analysts at Royal Bank of Canada

April 15, 2024 | markets.businessinsider.com

RBC Capital Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)

April 12, 2024 | investing.com

4D Molecular Therapeutics Inc (FDMT)

April 4, 2024 | finance.yahoo.com

4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares

March 29, 2024 | finance.yahoo.com

4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company Shares

March 29, 2024 | markets.businessinsider.com

Optimistic Outlook for 4D Molecular Therapeutics Ahead of Regulatory Update on CF Gene Therapy 4D-710

March 28, 2024 | globenewswire.com

4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

March 4, 2024 | globenewswire.com

4DMT to Participate in Upcoming Investor Conferences

March 2, 2024 | finance.yahoo.com

4D Molecular Therapeutics Full Year 2023 Earnings: Misses Expectations

March 2, 2024 | finance.yahoo.com

4D Molecular Therapeutics Inc Reports Full Year 2023 Financial Results

February 29, 2024 | globenewswire.com

4DMT Reports Full Year 2023 Financial Results and Operational Highlights

February 24, 2024 | msn.com

4D Molecular Therapeutics (FDMT) Price Target Increased by 47.68% to 50.55

February 23, 2024 | benzinga.com

4D Molecular Therapeutics Stock (NASDAQ:FDMT) Dividends: History, Yield and Dates

February 13, 2024 | markets.businessinsider.com

Buy Rating on 4D Molecular Therapeutics Backed by Strong Clinical Results and Broad Commercial Prospects

February 12, 2024 | finance.yahoo.com

Institutional investors in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) lost 11% last week but have reaped the benefits of longer-term growth

February 12, 2024 | finance.yahoo.com

4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024

February 10, 2024 | msn.com

4D Molecular Therapeutics Secures Major Financial Deal

See More Headlines

Receive FDMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:FDMT
CUSIP: N/A
CIK: 1650648
Web: www.4dmoleculartherapeutics.com
Phone: 510-505-2680
Fax: N/A
Employees: 147
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $44.22
High Stock Price Target: $81.00
Low Stock Price Target: $24.00
Potential Upside/Downside: +75.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.66)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-100,840,000.00
Net Margins: -436.30%
Pretax Margin: -486.60%
Return on Equity: -34.14%
Return on Assets: -31.07%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.65
Quick Ratio: 15.65

Sales & Book Value

Annual Sales: $20.72 million
Price / Sales: 62.35
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.20 per share
Price / Book: 3.51

Miscellaneous

Outstanding Shares: 51,160,000
Free Float: 45,683,000
Market Cap: $1.29 billion
Optionable: Optionable
Beta: 2.87

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. John F. Milligan Ph.D. (Age 63)
Executive Chairman
Comp: $150k
Dr. David H. Kirn M.D. (Age 62)
Co-Founder, CEO & Director
Comp: $920.97k
Dr. Fariborz Kamal Ph.D. (Age 61)
President & COO
Comp: $678.4k
Dr. Noriyuki Kasahara M.D. (Age 61)
Ph.D., Chief Scientific Officer
Comp: $13.6k
Ms. Theresa Janke (Age 49)
Co-Founder & Chief of Staff
Comp: $652.32k
Mr. Uneek Mehra (Age 52)
Chief Financial & Business Officer
Dr. Scott P. Bizily J.D. (Age 51)
Ph.D., Chief Legal Officer & Corporate Secretary
Dr. Robert Y. Kim M.B.A. (Age 63)
M.D., Chief Medical Officer
Dr. An Song Ph.D.
Chief Development Officer
Dr. Alan H. Cohen FAAAAI (Age 63)
FAAP, FACAAI, FCCP, M.D., Senior VP & Therapeutic Area Head of Pulmonology

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FDMT Stock Analysis - Frequently Asked Questions

Should I buy or sell 4D Molecular Therapeutics stock right now?: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 4D Molecular Therapeutics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" FDMT shares.
View FDMT analyst ratings or view top-rated stocks.
What is 4D Molecular Therapeutics' stock price target for 2024?: 10 Wall Street research analysts have issued 1 year price targets for 4D Molecular Therapeutics' stock. Their FDMT share price targets range from $24.00 to $81.00. On average, they predict the company's share price to reach $44.22 in the next year. This suggests a possible upside of 75.1% from the stock's current price.
View analysts price targets for FDMT or view top-rated stocks among Wall Street analysts.
How have FDMT shares performed in 2024?: 4D Molecular Therapeutics' stock was trading at $20.26 at the start of the year. Since then, FDMT stock has increased by 24.6% and is now trading at $25.25.
View the best growth stocks for 2024 here.
Are investors shorting 4D Molecular Therapeutics?: 4D Molecular Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 9,320,000 shares, an increase of 9.6% from the March 15th total of 8,500,000 shares. Based on an average daily volume of 1,170,000 shares, the short-interest ratio is presently 8.0 days.
View 4D Molecular Therapeutics' Short Interest.
When is 4D Molecular Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our FDMT earnings forecast.
How were 4D Molecular Therapeutics' earnings last quarter?: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) announced its quarterly earnings results on Thursday, February, 29th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by $0.09. The business had revenue of ($0.02) million for the quarter, compared to the consensus estimate of $4.67 million. 4D Molecular Therapeutics had a negative net margin of 436.30% and a negative trailing twelve-month return on equity of 34.14%.

What ETFs hold 4D Molecular Therapeutics' stock?: ETFs with the largest weight of 4D Molecular Therapeutics (NASDAQ:FDMT) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and ALPS Medical Breakthroughs ETF (SBIO).iShares Micro-Cap ETF (IWC).
When did 4D Molecular Therapeutics IPO?: 4D Molecular Therapeutics (FDMT) raised $101 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, Evercore ISI and William Blair acted as the underwriters for the IPO and Chardan was co-manager.
Who are 4D Molecular Therapeutics' major shareholders?: 4D Molecular Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include David Kirn, David Schaffer, Global Investors Lp Viking, Jacob Chacko, Robert Young Kim and Scott Bizily.
View institutional ownership trends.
How do I buy shares of 4D Molecular Therapeutics?: Shares of FDMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FDMT) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial